[go: up one dir, main page]

MX2010003765A - Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6. - Google Patents

Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6.

Info

Publication number
MX2010003765A
MX2010003765A MX2010003765A MX2010003765A MX2010003765A MX 2010003765 A MX2010003765 A MX 2010003765A MX 2010003765 A MX2010003765 A MX 2010003765A MX 2010003765 A MX2010003765 A MX 2010003765A MX 2010003765 A MX2010003765 A MX 2010003765A
Authority
MX
Mexico
Prior art keywords
compounds
pharmaceutically acceptable
disorders
stereoisomers
derivatives
Prior art date
Application number
MX2010003765A
Other languages
English (en)
Inventor
Nigori Venkata Satya Ramakrishna
Rama Sastri Kambhampati
Anil Karbhari Shinde
Nagaraj Vishwottam Kandikere
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2010003765A publication Critical patent/MX2010003765A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invenci?n se relaciona con compuestos novedosos de aminoarilsulfonamida de la f?rmula (I), sus derivados, sus estereois?meros, sus sales farmac?uticamente aceptables y las composiciones farmac?uticamente aceptables que los contienen. La presente invenci?n tambi?n se relaciona con un proceso para la preparaci?n de los compuestos novedosos anteriores, sus derivados, sus estereois?meros, sus sales farmac?uticamente aceptables y las composiciones farmac?uticamente aceptables que los contienen. Los compuestos de la invenci?n son ?tiles en el tratamiento de varios trastornos que est?n relacionados con las funciones del receptor de 5-HT6. De manera espec?fica, los compuestos de esta invenci?n tambi?n son ?tiles en el tratamiento de varios trastornos del CNS, trastornos hematol?gicos, trastornos de la alimentaci?n, obesidad, ansiedad, depresi?n, enfermedades asociadas con el dolor, enfermedades respiratorias, enfermedades gastrointestinales, cardiovasculares y c?ncer.
MX2010003765A 2007-10-26 2008-05-02 Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6. MX2010003765A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2433CH2007 2007-10-26
PCT/IN2008/000281 WO2009053997A1 (en) 2007-10-26 2008-05-02 Amino arylsulfonamide compounds and their use as 5-ht6 ligands

Publications (1)

Publication Number Publication Date
MX2010003765A true MX2010003765A (es) 2010-04-30

Family

ID=39769531

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003765A MX2010003765A (es) 2007-10-26 2008-05-02 Compuestos de aminoarilsulfonamida y su uso como ligandos de la 5-hidroxitriptamina6.

Country Status (20)

Country Link
US (1) US7964627B2 (es)
EP (1) EP2200980B9 (es)
JP (1) JP5236001B2 (es)
KR (1) KR101268654B1 (es)
CN (1) CN101835748B (es)
AT (1) ATE518833T1 (es)
AU (1) AU2008315309B2 (es)
BR (1) BRPI0816571A2 (es)
CA (1) CA2703157C (es)
CY (1) CY1112181T1 (es)
DK (1) DK2200980T3 (es)
EA (1) EA017154B1 (es)
ES (1) ES2370680T3 (es)
HR (1) HRP20110780T2 (es)
IL (1) IL205231A (es)
MX (1) MX2010003765A (es)
NZ (1) NZ585374A (es)
SI (1) SI2200980T1 (es)
WO (1) WO2009053997A1 (es)
ZA (1) ZA201002165B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102153884B (zh) * 2011-02-16 2013-06-19 连云港清泰化工有限公司 一种墨水型染料及其制备方法与用途
EP2763676B1 (en) 2011-10-03 2019-12-25 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
WO2013116732A1 (en) * 2012-02-02 2013-08-08 Curelon Llc Enzyme compositions and use thereof for wound healing
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
TR201903344T4 (tr) * 2014-08-16 2019-04-22 Suven Life Sciences Ltd 1-[(2-bromofenil) sülfonil]-5-metoksi-3- [(4-metil-1-piperazinil) metil]-1H-indol dimesilat monohidratın aktif metaboliti ve aktif metabolitin dimesilat dihidrat tuzu.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
HUP0003073A3 (en) 1997-07-11 2002-10-28 Smithkline Beecham Plc Benzenesulfonamide derivatives, process for producing them and their use as medicines
DE69906397T2 (de) * 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
JP4597386B2 (ja) 1999-04-21 2010-12-15 エヌピーエス ファーマシューティカルス,インコーポレーテッド 5−ht6親和性を有するピペリジン−インドール化合物
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
AU2002236730B2 (en) 2001-01-30 2006-06-15 Eli Lilly And Company Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-HT6 receptor
EP1383767A1 (en) 2001-02-08 2004-01-28 Memory Pharmaceutical Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
NZ529631A (en) 2001-06-07 2006-08-31 F Indole derivatives with 5-hydroxytryptamine (5-HT) 5-HT6 receptor affinity in the treatment of disorders of the CNS
US20050255529A1 (en) 2002-02-01 2005-11-17 Stefan Golz Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
WO2003066056A1 (en) 2002-02-05 2003-08-14 Glaxo Group Limited Method of promoting neuronal growth
SI1497266T1 (sl) 2002-03-27 2008-10-31 Glaxo Group Ltd Derivati kinolina in njihova uporaba kot ligandi 5-ht6
KR20050073560A (ko) * 2002-10-18 2005-07-14 에프. 호프만-라 로슈 아게 5-ht6 수용체 친화성을 갖는 4-피페라진일 벤젠설폰일인돌
WO2004048328A2 (en) * 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylsulfonyl-3-aminoalkoxyindoles
PT1581492E (pt) 2002-11-28 2008-09-19 Suven Life Sciences Ltd Indoles n-arilsulfonil-3-substituídos possuindo afinidade de receptor de serotonina, processo para a sua preparação e composição farmacêutica contendo os mesmos
AU2003292508A1 (en) 2002-11-28 2004-06-18 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
MXPA05005808A (es) 2002-12-18 2005-09-08 Suven Life Sciences Ltd Indoles tetraciclicos sustituidos en la posicion 3 que tienen afinidad por el receptor de la serotonina.
WO2007020652A1 (en) 2005-08-12 2007-02-22 Suven Life Sciences Limited Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands.

Also Published As

Publication number Publication date
HRP20110780T1 (hr) 2011-11-30
EP2200980B1 (en) 2011-08-03
JP5236001B2 (ja) 2013-07-17
AU2008315309B2 (en) 2011-06-09
NZ585374A (en) 2011-09-30
JP2011500792A (ja) 2011-01-06
EP2200980B9 (en) 2011-12-28
US20100216861A1 (en) 2010-08-26
EA201070527A1 (ru) 2010-10-29
ZA201002165B (en) 2011-05-25
KR20100069707A (ko) 2010-06-24
HRP20110780T2 (hr) 2018-06-29
SI2200980T1 (sl) 2011-12-30
EP2200980A1 (en) 2010-06-30
CA2703157A1 (en) 2009-04-30
IL205231A0 (en) 2010-12-30
US7964627B2 (en) 2011-06-21
WO2009053997A1 (en) 2009-04-30
ES2370680T9 (es) 2012-02-15
BRPI0816571A2 (pt) 2015-12-22
ES2370680T3 (es) 2011-12-21
CN101835748A (zh) 2010-09-15
DK2200980T3 (da) 2011-11-21
AU2008315309A1 (en) 2009-04-30
CY1112181T1 (el) 2015-12-09
ATE518833T1 (de) 2011-08-15
EA017154B1 (ru) 2012-10-30
CA2703157C (en) 2013-02-05
HK1147750A1 (en) 2011-08-19
CN101835748B (zh) 2012-11-14
IL205231A (en) 2014-03-31
KR101268654B1 (ko) 2013-05-29

Similar Documents

Publication Publication Date Title
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
UA98961C2 (uk) Похідні піразинону та їх застосування у лікуванні легеневих захворювань
JO2701B1 (en) Vehicles
JO2686B1 (en) Vehicles
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
IL205231A0 (en) Amino arylsulfonamide compounds and their use as 5 - ht6 ligands
TW200604182A (en) Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments
MX2009006077A (es) Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6.
IL201491A0 (en) Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
TW200716547A (en) Piperidin-4-yl-amide derivatives
WO2009027736A3 (en) 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
TW200640863A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
MX2009006757A (es) Compuestos de 4-(heterociclil)alquil-n-(arilsulfonil) indol y su uso como ligandos de la 5-hidroxitriptamina6.
MX2013001988A (es) Compuestos de heterociclilo comoligandos del receptor h3 de la histamina
MX2011008857A (es) Derivados de oxiindol con actividad agonistica del receptor de motilina.
TW200728281A (en) Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
MX2009007042A (es) S-nitrosotioles estables, procedimiento de sintesis y uso.

Legal Events

Date Code Title Description
FG Grant or registration